Researchers found that bioengineered CAR-T cells when mixed with other immune cells can "donate" proteins, suggesting ...

A study of 783 patients treated with CAR T cell therapy found no evidence that the therapy itself caused secondary cancers.

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the ...

A major limitation of this type of CAR T cell therapy, called autologous therapy, is that the cells are taken from the ...

PHC and CCRM Collaborate to Develop Primary T-Cell Expansion Culture Processes to Enhance Efficiency and Improve Cell Quality ...

NecstGen Clean Cleanroom for CAR-T Production NecstGen, a leading Contract Development and Manufacturing Organization (CDMO) dedicated to C ...

PHC has partnered with CCRM to boost cell quality with advanced T-cell expansion solutions. Takeaway Points  PHC has ...

A revolutionary approach to immune therapy has emerged: engineered immune cells that protect healthy tissue without ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the first ...

In the wake of its success in cancer therapy, adoptive transfer of engineered T cells modified with chimeric antigen receptors (CAR) for target recognition could now become a therapeutic option for ...

Unlike CAR-T cells, NK cells don’t need genetic modification to recognize a specific threat — they act broadly without ...